Kyverna Therapeutics Inc KYTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
-
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
-
Kyverna Therapeutics to Present at Upcoming Investor Conferences
-
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
-
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Trading Information
- Previous Close Price
- $5.97
- Day Range
- $5.64–6.05
- 52-Week Range
- $5.61–13.67
- Bid/Ask
- $5.62 / $6.30
- Shares Outstanding
- 61.84M
- Market Cap
- $350.65M
- Volume/Avg
- 726,278 / 857,807
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 149
- Website
- https://www.kyvernatx.com
Valuation
|
Metric
|
KYTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KYTX
|
|---|---|
Quick Ratio | 8.75 |
Current Ratio | 9.06 |
Interest Coverage | −88.73 |
Quick Ratio
KYTX
Profitability
|
Metric
|
KYTX
|
|---|---|
Return on Assets (Normalized) | −59.34% |
Return on Equity (Normalized) | −75.58% |
Return on Invested Capital (Normalized) | −70.87% |
Return on Assets
KYTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x&fGDzx | LOCK|?^J@ | $127B | |||
| Moderna Inc
MRNA
| LOCK|HVX%<q | LOCK|$G | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V$N?^&D | LOCK|gh#>p | $81B | |||
| argenx SE ADR
ARGX
| LOCK|NnXcD!@ | LOCK|@< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|nBmJj&T | LOCK|!?L | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vTSrnC | LOCK|!&cJc | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#$^B<tzy | LOCK|b>^$< | $27B | |||
| Incyte Corp
INCY
| LOCK|<hYKZS | LOCK|?&Y | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?^mrTGm | LOCK|hQT | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&yp#HLF | LOCK|&Cy | $14B |
United States